- Home
- Industry Reports
- Biotechnology
- Healthcare
- Asia Pacific Biologics Market – Size, Outlook, Trends and Forecast (2023 – 2030)
Diseases like cancer, rheumatoid arthritis and many more rare diseases for which there were no previous treatment options are treated by using biologics. Medical products originated from living organisms are considered biologic products. Biologics are the new class of protein-based therapeutics that are produced using living organisms, including plants, animals, and microorganisms such as yeast & bacteria.
APAC Biologics Market Size & Growth:
The APAC biologics market was valued to be nearly $XX billion in 2017 and is expected to reach over $XX billion by the end of 2025 with a CAGR of XX% during the APAC biologics market forecasts period 2019-2025. Stringent regulatory process & high capital investment are significantly restraining the market growth. Since biologics drugs are highly complex & required to control & maintain throughout the development & production process. This regulated environment & quality control procedures involve huge capital investment in the initial state of the process. Additionally, biologics are most susceptible to light, heat conditions and need an auspicious environment which is not uniform across the globe. In most emerging markets, biologics has little presence and is one among the promising markets across the globe. Stringent regulatory policies and high-capital investment coupled with limited patient access to reasonable biologics mainly in the developing countries owing to the increasing control and cost for accessing biologics are likely to obstruct the growth of the APAC biologics market. Some of the key drivers that are driving APAC biologics market growth are increasing capital investment from critical players, rising prevalence of chronic diseases, growing demand & higher acceptability for innovative therapies and others. Increase in population & changes in social behaviour is contributing to a steady rise in these common & costly long-term health problems. The middle class is increasing and the urbanisation fast-tracking, people are adopting a more inactive lifestyle. This is increasing obesity rates and causing leading to diabetes on top. Based on the World Health Organization report, chronic disease prevalence is expected to rise by 57% by the year 2020. Emerging markets will be hardest hit as population growth is expected to be most significant in developing nations. Based on the APAC biologics market outlook, the cancer application market size is estimated to proliferate. Since the demand for usage of biologics in cancer treatment. According to APAC biologics market analysis, APAC biologics market size will increase eventually high in the forecast period from 2019-2025.
APAC Biologics Market Share:
APAC biologics market is segmented by type, products, application and geography. By the product, the market in monoclonal antibodies segment of the biologics market is estimated to grow at the fastest CAGR during the forecast period. These antibodies are made by different immune cells that are all clones of a unique parent cell. These antibodies have a monovalent affinity, and they bind to the same epitope and are used to treat cancer. Regarding application, the market in cancer application of the biologics market is estimated to grow at the fastest CAGR during the forecast period. This growth can be due to increasing demand for biologics in the treatment of cancer to kill cancer cells by body immune system.
Concerning geography, the market is segmented into China, Japan, India, Australia and New Zealand. China is predicted to be a dominant market in the biologics market during 2019 – 2025. China has the significant biologics teams in the world and consequently produces high demand for biologics. India is said to be the fastest growing market regarding biologics. Rising conciseness regarding health & increasing population is boosting the biologics market.
APAC Biologics Market Trends:
- July 2018, New Cell lines produce NIST monoclonal antibody for improved biologic drugs.
- August 2018, while facing authorisations, Samsung ups its investment in biologics.
APAC Biologics Market Research Report:
- An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
- To have a complete market analysis through industry value chain analysis, Porter’s five, PESTLE, SWOTanalysis, and Y-o-Y analysis.
- Regional and APAC diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year–On–Year
- Identifying DROC in the current market and their impact on altering market dynamics.
- Competitive landscape analysis to identify the merger and acquisition which will have a comparative financial analysis with significant competitors.
- Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
- Identify the latest developments, market shares and strategies that are employed by the major market players, such as
- Prana Biotechnologies
- BTG
- Merck & Co
- Novo Nordisk
- Lonza.
- Biomarin
- Pfizer Inc.
- TOT Biopharm
- Allergan Plc.
- Johnson & Johnson
- AGC Biologics
- Astellas Pharma Inc.
1. Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
3. Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Force Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analysis
4. Market Dynamics
4.1. Drivers
4.1.1. Growing demand & higher acceptability for innovative therapies
4.1.2. Loss of patent exclusivity of the leading biologics drugs
4.1.3. Increasing capital investment from critical players
4.1.4. Rising prevalence of chronic diseases
4.2. Restraints & Challenges:
4.2.1. Stringent regulatory process & Initial high capital investment
4.2.2. Rising control & cost for accessing biologics
4.3. Opportunities
4.3.1. Technology advancements & drug innovations
5. APAC Biologics Market – By Product
5.1. Introduction
5.2. Monoclonal Antibodies
5.3. Vaccines
5.4. Recombinant harmonies/proteins
5.5. Cell Therapy
5.6. Gene Therapy
5.7. Others
6. APAC Biologics Market – By Applications
6.1. Introduction
6.2. Cancer
6.3. Infectious Diseases
6.4. Rare Diseases
6.5. Autoimmune Diseases
6.6. Others
7. APAC Biologics Market – By Geography
7.1. Introduction
7.2. APAC
7.2.1. China
7.2.2. Japan
7.2.3. India
7.2.4. Australia & New Zealand
7.2.3. Rest of APAC
8. Company Profiles
8.1. AbbVie Inc.
8.1.1. Company Overview
8.1.2. Business Segments
8.1.3. Financials (Public Companies)
8.1.4. Developments
8.1.5. SWOT Analysis (Public Companies)
8.2. Prana Biotechnologies
8.3. BTG PLC
8.4. Merck & Co
8.5. Novo Nordisk
8.6. Lonza Group
8.7. BioMarin Pharmaceutical
8.8. Pfizer Inc.
8.9. Astellas Pharma Inc.
8.10. Johnson & Johnson
8.11. Allergan plc
8.12. MJ Biopharm Pvt. Ltd.
8.13. AGC Biologics
9. Competitive Landscape
9.1. Market Share Analysis
9.2. Strategies Adopted by top companies
9.3. Mergers, Acquisitions, Collaborations & Agreements
10. Market Insights
10.1. Industry Experts Insights
10.2. Analysts Opinions
10.3. Investment Opportunities
11. Appendix
11.1 List of Tables
11.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Regional Report
$2,160.00 – $7,200.00
- EUR: €2,049.53 - €6,831.77
- INR: ₹179,619.81 - ₹598,732.71
- AED: د.إ7,927.20 - د.إ26,424.00
- GBP: £1,769.42 - £5,898.07
Description
Regional Reports
Additional information
Report Type | Extensive Report, Miniature report, Snapshot Report |
---|---|
Licence | Single User License, Team License, Corporate License |
Diseases like cancer, rheumatoid arthritis and many more rare diseases for which there were no previous treatment options are treated by using biologics. Medical products originated from living organisms are considered biologic products. Biologics are the new class of protein-based therapeutics that are produced using living organisms, including plants, animals, and microorganisms such as yeast & bacteria.
APAC Biologics Market Size & Growth:
The APAC biologics market was valued to be nearly $XX billion in 2017 and is expected to reach over $XX billion by the end of 2025 with a CAGR of XX% during the APAC biologics market forecasts period 2019-2025. Stringent regulatory process & high capital investment are significantly restraining the market growth. Since biologics drugs are highly complex & required to control & maintain throughout the development & production process. This regulated environment & quality control procedures involve huge capital investment in the initial state of the process. Additionally, biologics are most susceptible to light, heat conditions and need an auspicious environment which is not uniform across the globe. In most emerging markets, biologics has little presence and is one among the promising markets across the globe. Stringent regulatory policies and high-capital investment coupled with limited patient access to reasonable biologics mainly in the developing countries owing to the increasing control and cost for accessing biologics are likely to obstruct the growth of the APAC biologics market. Some of the key drivers that are driving APAC biologics market growth are increasing capital investment from critical players, rising prevalence of chronic diseases, growing demand & higher acceptability for innovative therapies and others. Increase in population & changes in social behaviour is contributing to a steady rise in these common & costly long-term health problems. The middle class is increasing and the urbanisation fast-tracking, people are adopting a more inactive lifestyle. This is increasing obesity rates and causing leading to diabetes on top. Based on the World Health Organization report, chronic disease prevalence is expected to rise by 57% by the year 2020. Emerging markets will be hardest hit as population growth is expected to be most significant in developing nations. Based on the APAC biologics market outlook, the cancer application market size is estimated to proliferate. Since the demand for usage of biologics in cancer treatment. According to APAC biologics market analysis, APAC biologics market size will increase eventually high in the forecast period from 2019-2025.
APAC Biologics Market Share:
APAC biologics market is segmented by type, products, application and geography. By the product, the market in monoclonal antibodies segment of the biologics market is estimated to grow at the fastest CAGR during the forecast period. These antibodies are made by different immune cells that are all clones of a unique parent cell. These antibodies have a monovalent affinity, and they bind to the same epitope and are used to treat cancer. Regarding application, the market in cancer application of the biologics market is estimated to grow at the fastest CAGR during the forecast period. This growth can be due to increasing demand for biologics in the treatment of cancer to kill cancer cells by body immune system.
Concerning geography, the market is segmented into China, Japan, India, Australia and New Zealand. China is predicted to be a dominant market in the biologics market during 2019 – 2025. China has the significant biologics teams in the world and consequently produces high demand for biologics. India is said to be the fastest growing market regarding biologics. Rising conciseness regarding health & increasing population is boosting the biologics market.
APAC Biologics Market Trends:
- July 2018, New Cell lines produce NIST monoclonal antibody for improved biologic drugs.
- August 2018, while facing authorisations, Samsung ups its investment in biologics.
APAC Biologics Market Research Report:
- An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
- To have a complete market analysis through industry value chain analysis, Porter’s five, PESTLE, SWOTanalysis, and Y-o-Y analysis.
- Regional and APAC diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year–On–Year
- Identifying DROC in the current market and their impact on altering market dynamics.
- Competitive landscape analysis to identify the merger and acquisition which will have a comparative financial analysis with significant competitors.
- Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
- Identify the latest developments, market shares and strategies that are employed by the major market players, such as
- Prana Biotechnologies
- BTG
- Merck & Co
- Novo Nordisk
- Lonza.
- Biomarin
- Pfizer Inc.
- TOT Biopharm
- Allergan Plc.
- Johnson & Johnson
- AGC Biologics
- Astellas Pharma Inc.
1. Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
3. Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Force Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analysis
4. Market Dynamics
4.1. Drivers
4.1.1. Growing demand & higher acceptability for innovative therapies
4.1.2. Loss of patent exclusivity of the leading biologics drugs
4.1.3. Increasing capital investment from critical players
4.1.4. Rising prevalence of chronic diseases
4.2. Restraints & Challenges:
4.2.1. Stringent regulatory process & Initial high capital investment
4.2.2. Rising control & cost for accessing biologics
4.3. Opportunities
4.3.1. Technology advancements & drug innovations
5. APAC Biologics Market – By Product
5.1. Introduction
5.2. Monoclonal Antibodies
5.3. Vaccines
5.4. Recombinant harmonies/proteins
5.5. Cell Therapy
5.6. Gene Therapy
5.7. Others
6. APAC Biologics Market – By Applications
6.1. Introduction
6.2. Cancer
6.3. Infectious Diseases
6.4. Rare Diseases
6.5. Autoimmune Diseases
6.6. Others
7. APAC Biologics Market – By Geography
7.1. Introduction
7.2. APAC
7.2.1. China
7.2.2. Japan
7.2.3. India
7.2.4. Australia & New Zealand
7.2.3. Rest of APAC
8. Company Profiles
8.1. AbbVie Inc.
8.1.1. Company Overview
8.1.2. Business Segments
8.1.3. Financials (Public Companies)
8.1.4. Developments
8.1.5. SWOT Analysis (Public Companies)
8.2. Prana Biotechnologies
8.3. BTG PLC
8.4. Merck & Co
8.5. Novo Nordisk
8.6. Lonza Group
8.7. BioMarin Pharmaceutical
8.8. Pfizer Inc.
8.9. Astellas Pharma Inc.
8.10. Johnson & Johnson
8.11. Allergan plc
8.12. MJ Biopharm Pvt. Ltd.
8.13. AGC Biologics
9. Competitive Landscape
9.1. Market Share Analysis
9.2. Strategies Adopted by top companies
9.3. Mergers, Acquisitions, Collaborations & Agreements
10. Market Insights
10.1. Industry Experts Insights
10.2. Analysts Opinions
10.3. Investment Opportunities
11. Appendix
11.1 List of Tables
11.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Our Clientele
Exclusive Benefits
Credibility and Transparency
We actively recruit consumers, business professionals, and hard-to-reach individuals as members of our research panels, and we build trusted, ongoing relationships with them. Thus we provide the complete list of primary and secondary data sources in the report to maintain the transparency and to assure the credibility.
Exhaustive Coverage
Detailed and extensive coverage in the geography.Survey consultation for brand tracking, concept testing, consumer behaviour, and more, we have you covered with market research services that scale to meet your needs.
Competitive Edge
Our reports cover most recent updates in the market till the date of the purchase. We identify, gather and timely deliver analysis on impact of unprecedented decisions of CXOs in COVID-19 catastrophe on many businesses, their clients and their clients' clients without additional cost.
Golden Opportunities
A comprehensive strategic sieve analysis of the market by our analysts and consultants, aided by AI tools helps us find the non-obvious, golden and emerging opportunities for you to evaluate.
Top-notch Reports Guaranteed
70% of our research is exclusive; no other research firm has the depth and breadth of our research.
Post Purchase Support
Post-purchase support is provided for all our reports, for three months from the date of purchase, where related queries will be answered within 24 business hours over telephone or email.